NervGen Pharma to Delist from TSXV on March 16, Focus on NVG-291 Trials
NervGen Pharma will voluntarily delist shares from the TSX Venture Exchange on March 16, 2026, cutting duplicative fees and regulatory complexity and retaining Nasdaq trading access. The action aligns with its move to late-stage development for NVG-291 and ends an ATM equity program that raised US$1,489 by issuing 245 shares.
1. Voluntary TSXV Delisting
On March 16, 2026, NervGen Pharma will remove its common shares from the TSX Venture Exchange, consolidating its listing exclusively on Nasdaq under the symbol NGEN. Shareholders need take no action and will retain unrestricted trading access on Nasdaq after the delisting.
2. Strategic Cost Reduction and Focus on NVG-291
The company expects to eliminate duplicative exchange fees and reduce legal, accounting and regulatory burdens, enabling management to concentrate on clinical execution. This decision supports NervGen’s progression into late-stage development for its lead neuroreparative candidate, NVG-291.
3. Termination of ATM Equity Program
In connection with the TSXV delisting, NervGen has ended its at-the-market equity program launched December 19, 2025. From January 1 through March 12 the program issued 245 common shares at a weighted average price of US$6.20, generating net proceeds of US$1,489.